Table 1.
Patient characteristics (n = 57)
| HAdV infection | No HAdV infection | P | |||
|---|---|---|---|---|---|
| N = 11 | % or range | N = 46 | % or range | ||
| Median age at HCT, years | 5.2 | 0.7‐17.5 | 5.5 | 0.6‐18.1 | .8 |
| Sex, male | 6 | 17 | 30 | 84 | .5 |
| Diagnosis | .2 | ||||
| Acute leukemia (AML/ALL) | 5 | 29 | 12 | 71 | |
| Aplastic anemia | 2 | 20 | 8 | 80 | |
| Neuroblastoma (all relapsed) | 3 | 27 | 8 | 73 | |
| Primary immunodeficiency disease | 1 | 20 | 4 | 80 | |
| Othersa | 0 | 0 | 14 | 100 | |
| Relapsed statusb | 6 | 29 | 15 | 71 | .3 |
| Donor type | .2 | ||||
| MRD (sibling) | 3 | 50 | 3 | 50 | |
| MUD | 6 | 15 | 33 | 85 | |
| MMRD (haploidentical) | 2 | 17 | 10 | 83 | |
| Donor cell source | .7 | ||||
| Peripheral blood | 9 | 22 | 32 | 78 | |
| Cord blood | 2 | 13 | 14 | 88 | |
| CD34 cell dose (x106 cells/kg) | |||||
| Peripheral blood | 9.2 | 1.6‐30.1 | 5.3 | 1.6‐16.6 | .1 |
| Cord blood | 0.3 | 0.2‐0.4 | 0.1 | 0.02‐1.6 | .6 |
| Conditioning intensity | .7 | ||||
| Myeloablative | 8 | 18 | 36 | 82 | |
| Reduced | 3 | 23 | 10 | 77 | |
| Conditioning regimen | .8 | ||||
| TBI‐based | 4 | 27 | 11 | 73 | |
| Busulfan‐based | 4 | 17 | 20 | 83 | |
| Others | 3 | 17 | 15 | 83 | |
| Use of ATG | 6 | 17 | 29 | 83 | .7 |
| Recipients’ pre‐HCT surveillance | |||||
| Respiratory virus (by PCR)c | 10 | 19 | 43 | 81 | 1.0 |
| CMV seropositivity | 10 | 19 | 44 | 81 | .5 |
| HSV seropositivity | 9 | 20 | 35 | 80 | 1.0 |
| Median neutrophil engraftment, days | 12 | 9‐19 | 12 | 8‐25 | .7 |
| Median dose of max. steroid until day 100, (mg/kg/d) | 2 | 0‐2 | 2 | 0‐10 | .4 |
| Infectious complication until day 100 | |||||
| CMV Antigenemia or diseased | 8 | 17 | 38 | 83 | .4 |
| EBV viremia | 3 | 18 | 14 | 82 | 1.0 |
| BKV cystitis | 7 | 19 | 30 | 81 | 1.0 |
| Other respiratory virus infection | 2 | 17 | 10 | 83 | 1.0 |
| Bacteraemia | 1 | 17 | 5 | 83 | 1.0 |
| Invasive fungal infectione | 1 | 20 | 4 | 80 | 1.0 |
| Acute GVHD ≥3 | 2 | 15 | 11 | 85 | 1.0 |
| Chronic GVHD | 5 | 22 | 18 | 78 | 1.0 |
| Extensive | 3 | 23 | 8 | 77 | 1.0 |
| N/A | – | – | |||
HAdV indicates human adenovirus; HCT, hematopoietic cell transplantation; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; MRD, matched related donor; MUD, matched unrelated donor; MMRD, mismatched related donor; TBI, total body irradiation; ATG, antithymocyte globulin; PCR, polymerase chain reaction; CMV, cytomegalovirus; HSV, herpes simplex virus; EBV, Epstein–Barr virus; BKV, BK virus; GVHD, graft‐vs‐host disease; N/A, not applicable.
Included 4 cases of juvenile myelomonocytic leukemia (JMML), 2 cases of hemophagocytic lymphohistiocytosis (HLH), 2 cases of myelodysplastic syndromes (MDS), 2 cases of sarcoma, 1 case of Fanconi anemia, 1 case of non‐Hodgkin lymphoma, 1 case of pure red cell aplasia, and 1 case of retinoblastoma.
The relapsed state was defined as a return of a malignant disease or the signs and symptoms of a disease after a period of improvement.
Among 53 recipients who had been tested pre‐HCT by multiplex respiratory virus PCR, 5 cases had respiratory virus detected (all rhinovirus).
All 47 recipients were treated with ganciclovir. Forty‐four patients had CMV antigenemia only and 3 recipients had CMV disease.
All 5 patients had invasive pulmonary aspergillosis (IPA) infection. Four cases were probable and 1 case was possible IPA.
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.